Developing small molecules to address unmet medical needs
Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneTM technology to adjust the chemical and physical properties of inositol phosphate (IP6) analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. The lead compound INS-3001 is a cardiovascular calcification inhibitor in development for aortic valve stenosis. Inositec was founded in December 2015 based on the award-winning research of Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux and Prof. Bastien Castagner at ETH Zurich, Switzerland. Further information can be found at www.inositec.com.
